United States - English - NLM (National Library of Medicine)

bi-coastal pharma international llc - cephalexin (unii: obn7uds42y) (cephalexin anhydrous - unii:5sff1w6677) - cephalexin anhydrous 250 mg - cephalexin capsules are indicated for the treatment of the following infections when caused by susceptible strains of the designated microorganisms: respiratory tract infections caused by streptococcus pneumoniae and streptococcus pyogenes (penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. cephalexin is generally effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of cephalexin in the subsequent prevention of rheumatic fever are not available at present.) otitis media due to streptococcus pneumoniae, haemophilus influenzae, staphylococcus aureus, streptococcus pyogenes , and moraxella catarrhalis skin and skin structure infections caused by staphylococcus aureus and/or streptococcus pyogenes bone infections caused by staphylococcus aureus and/or proteus mirabilis genitourinary tract infections, including acute prostatitis, caused by escherichia

United States - English - NLM (National Library of Medicine)

lupin limited - cephalexin (unii: obn7uds42y) (cephalexin anhydrous - unii:5sff1w6677) - cephalexin anhydrous 250 mg - cephalexin capsules usp are indicated for the treatment of respiratory tract infections caused by susceptible isolates of streptococcus pneumoniae and streptococcus pyogenes . cephalexin capsules usp are indicated for the treatment of otitis media caused by susceptible isolates of streptococcus pneumoniae , haemophilus influenzae , staphylococcus aureus , streptococcus pyogenes , and moraxella catarrhalis . cephalexin capsules usp are indicated for the treatment of skin and skin structure infections caused by susceptible isolates of the following gram-positive bacteria: staphylococcus aureus and streptococcus pyogenes . cephalexin capsules usp are indicated for the treatment of bone infections caused by susceptible isolates of staphylococcus aureus and proteus mirabilis . cephalexin capsules usp are indicated for the treatment of genitourinary tract infections, including acute prostatitis, caused by susceptible isolates of escherichia coli , proteus mirabilis , and klebsiella pneumoniae . to reduce the dev

United States - English - NLM (National Library of Medicine)

aidarex pharmaceuticals llc - cephalexin (unii: obn7uds42y) (cephalexin anhydrous - unii:5sff1w6677) - cephalexin anhydrous 250 mg in 5 ml - cephalexin is indicated for the treatment of the following infections when caused by susceptible strains of the designated microorganisms: respiratory tract infections caused by s. pneumoniae and s. pyogenes . (penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. cephalexin is generally effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of cephalexin in the subsequent prevention of rheumatic fever are not available at present.) otitis media due to s. pneumoniae, h. influenzae , staphylococci, streptococci, and m. catarrhalis . skin and skin structure infections caused by staphylococci and/or streptococci. bone infections caused by staphylococci and/or p. mirabilis . genitourinary tract infections, including acute prostatitis, caused by e. coli, p. mirabilis, and k. pneumoniae. note – culture and susceptibility tests should be initiated prior to and

United States - English - NLM (National Library of Medicine)

proficient rx lp - cephalexin (unii: obn7uds42y) (cephalexin anhydrous - unii:5sff1w6677) - cephalexin anhydrous 250 mg in 5 ml - cephalexin is indicated for the treatment of the following infections when caused by susceptible strains of the designated microorganisms: respiratory tract infections caused by streptococcus pneumoniae and streptococcus pyogenes (penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. cephalexin is generally effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of cephalexin in the subsequent prevention of rheumatic fever are not available at present.) otitis media due to streptococcus pneumoniae, haemophilus influenzae , staphylococcus aureus , streptococcus pyogenes , and moraxella catarrhalis skin and skin structure infections caused by staphylococcus aureus and/or streptococcus pyogenes bone infections caused by staphylococcus aureus and/or proteus mirabilis genitourinary tract infections, including acute prostatitis, caused by escherichia coli, pr

United States - English - NLM (National Library of Medicine)

medvantx, inc. - cephalexin (unii: obn7uds42y) (cephalexin anhydrous - unii:5sff1w6677) - cephalexin anhydrous 250 mg in 5 ml - cephalexin is indicated for the treatment of the following infections when caused by susceptible strains of the designated microorganisms: respiratory tract infections caused by streptococcus pneumoniae and streptococcus pyogenes (penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. cephalexin is generally effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of cephalexin in the subsequent prevention of rheumatic fever are not available at present.) otitis media due to streptococcus pneumoniae, haemophilus influenzae , staphylococcus aureus , streptococcus pyogenes , and moraxella catarrhalis skin and skin structure infections caused by staphylococcus aureus and/or streptococcus pyogenes bone infections caused by staphylococcus aureus and/or proteus mirabilis genitourinary tract infections, including acute prostatitis, caused by escherichia coli, pr

United States - English - NLM (National Library of Medicine)

preferred pharmaceuticals, inc. - cephalexin (unii: obn7uds42y) (cephalexin anhydrous - unii:5sff1w6677) - cephalexin anhydrous 125 mg in 5 ml - cephalexin is indicated for the treatment of respiratory tract infections caused by susceptible isolates of streptococcus pneumoniae and streptococcus pyogenes. cephalexin is indicated for the treatment of otitis media caused by susceptible isolates of streptococcus pneumoniae , haemophilus influenzae , staphylococcus aureus , streptococcus pyogenes , and moraxella catarrhalis. cephalexin is indicated for the treatment of skin and skin structure infections caused by susceptible isolates of the following gram-positive bacteria: staphylococcus aureus and streptococcus pyogenes . cephalexin is indicated for the treatment of bone infections caused by susceptible isolates of staphylococcus aureus and proteus mirabilis. cephalexin is indicated for the treatment of genitourinary tract infections, including acute prostatitis, caused by susceptible isolates of escherichia coli , proteus mirabilis , and klebsiella pneumoniae . to reduce the development of drug-resistant bacteria and maintain the effectiveness of cep

United States - English - NLM (National Library of Medicine)

orchidpharma inc - cephalexin (unii: obn7uds42y) (cephalexin anhydrous - unii:5sff1w6677) - cephalexin anhydrous 125 mg in 5 ml - cephalexin for oral suspension is indicated for the treatment of respiratory tract infections caused by susceptible isolates of streptococcus pneumoniae and streptococcus pyogenes . cephalexin for oral suspension is indicated for the treatment of otitis media caused by susceptible isolates of streptococcus pneumoniae , haemophilus influenzae , staphylococcus aureus , streptococcus pyogenes , and moraxella catarrhalis . cephalexin for oral suspension is indicated for the treatment of skin and skin structure infections caused by susceptible isolates of the following gram-positive bacteria: staphylococcus aureus and streptococcus pyogenes . cephalexin for oral suspension is indicated for the treatment of bone infections caused by susceptible isolates of staphylococcus aureus and proteus mirabilis. cephalexin for oral suspension is indicated for the treatment of genitourinary tract infections, including acute prostatitis, caused by susceptible isolates of escherichia coli , proteus mirabilis , and klebsiella p

United States - English - NLM (National Library of Medicine)

hikma pharmaceuticals usa inc. - cephalexin (unii: obn7uds42y) (cephalexin anhydrous - unii:5sff1w6677) - cephalexin 125 mg in 5 ml - cephalexin for oral suspension is indicated for the treatment of respiratory tract infections caused by susceptible isolates of streptococcus pneumoniae and streptococcus pyogenes . cephalexin for oral suspension is indicated for the treatment of otitis media caused by susceptible isolates of streptococcus pneumoniae , haemophilus influenzae , staphylococcus aureus , streptococcus pyogenes , and moraxella catarrhalis . cephalexin for oral suspension is indicated for the treatment of skin and skin structure infections caused by susceptible isolates of the following gram-positive bacteria: staphylococcus aureus and streptococcus pyogenes . cephalexin for oral suspension is indicated for the treatment of bone infections caused by susceptible isolates of staphylococcus aureus and proteus mirabilis . cephalexin for oral suspension is indicated for the treatment of genitourinary tract infections, including acute prostatitis, caused by susceptible isolates of escherichia coli , proteus mirabilis , and klebsiella

United States - English - NLM (National Library of Medicine)

rebel distributors corp - cephalexin (unii: obn7uds42y) (cephalexin anhydrous - unii:5sff1w6677) - cephalexin anhydrous 125 mg in 5 ml - cephalexin for oral suspension, usp is indicated for the treatment of the following infections when caused by susceptible strains of the designated microorganisms: respiratory tract infections caused by streptococcus pneumoniae and streptococcus pyogenes (penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. cephalexin for oral suspension, usp is generally effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of cephalexin in the subsequent prevention of rheumatic fever are not available at present.) otitis media due to streptococcus pneumoniae, haemophilus influenzae, staphylococcus aureus , streptococcus pyogenes , and moraxella catarrhalis skin and skin structure infections caused by staphylococcus aureus and/or streptococcus pyogenes bone infections caused by staphylococcus aureus and/or proteus mirabilis genitourinary tract infections, including

United States - English - NLM (National Library of Medicine)

orchidpharma inc - cephalexin (unii: obn7uds42y) (cephalexin anhydrous - unii:5sff1w6677) - cephalexin anhydrous 250 mg - cephalexin capsules are indicated for the treatment of respiratory tract infections caused by susceptible isolates of streptococcus pneumoniae and streptococcus pyogenes . cephalexin capsules are indicated for the treatment of otitis media caused by susceptible isolates of streptococcus pneumoniae , haemophilus influenzae, staphylococcus aureus, streptococcus pyogenes, and moraxella catarrhalis . cephalexin capsules are indicated for the treatment of skin and skin structure infections caused by susceptible isolates of the following gram-positive bacteria: staphylococcus aureus and streptococcus pyogenes . cephalexin capsules are indicated for the treatment of bone infections caused by susceptible isolates of staphylococcus aureus and proteus mirabilis . cephalexin capsules are indicated for the treatment of genitourinary tract infections, including acute prostatitis, caused by susceptible isolates of escherichia coli, proteus mirabilis, and klebsiella pneumoniae . to reduce the development of drug-resist